[Skip to Content]
[Skip to Content Landing]
Views 60
Citations 0
Correction
March 29, 2018

Error in Abstract and Tables

JAMA Ophthalmol. Published online March 29, 2018. doi:10.1001/jamaophthalmol.2018.0795

In the Original Investigation titled “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial,”1 published online February 1, 2018, there were errors in the Abstract as well as Table 1 and Table 2. The last 3 percentage values in the penultimate sentence of the Results section of the Abstract should read “…55% of 31 (P = .96) with bevacizumab, and 45% of 38 vs 66% of 29 (P = .10) with ranibizumab.” In Table 1, row 31, column 4 should read “20/32 (20/25 to 20/40).” In Table 2, row 4, column 6, there should be a space between “11” and “(35.5).” This article was corrected online.

References
1.
Bressler  NM, Beaulieu  WT, Glassman  AR,  et al; Diabetic Retinopathy Clinical Research Network.  Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial.  JAMA Ophthalmol. 2018;136(3):257-269.PubMedGoogle ScholarCrossref
×